FDA Wants To Review Drug Companies' Posts And Tweets

Law360, New York (January 28, 2014, 5:47 PM EST) -- The U.S. Food and Drug Administration has issued draft guidance addressing some of the unique challenges of drug promotion in the age of social media. Specifically, the draft guidance sheds light on how to comply with the FDA's post-market submission requirements when interactive promotional media constantly changes. In laying out the criteria for how and when to submit interactive promotional media for post-market review, the FDA gives important insight into the type of social media promotion in which it is most interested; namely, all of it....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!